Abstract:Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal of all human malignancies. PDAC is generally refractory to conventional treatments with 7.7% five-year survival rate. Our study aimed to discover novel targets to reverse tumor radioresistance of PDAC. By establishment of PDAC patient-derived xenograft (PDX) tumors which were given fractionated radiation, our study detected the transcriptome patterns of tumor tissues before radiotherapy, treated with radiotherapy at a total dose of 10 Gy and 20 Gy and relapsed after the radiotherapy ended using RNA-seq. The radiosensitizing effect of Mek kinase inhibitor PD98059 was investigated in vitro by clonogenic survival assay, detection of DNA double-strand breaks (DSBs) and by flow cytometry analysis on cell apoptosis. By establishment of PDAC PDX tumors in BALB/c nude mice, the radiosensitizing effect of PD98059 was investigated in vivo. Our study found the delayed xenograft tumor growth in PDAC was significantly inhibited by fractionated radiation, while reactivated after the radiotherapy ended, inducing tumor relapse. The Mek kinase inhibitor PD98059 significantly radiosensitized PDAC cell lines by enhancing DSBs and inhibiting DNA damage repair, resulting in decreased clonogenic survival and increased tumor growth inhibitory effect. In vivo studies showed PD98059 significanlty delayed xenograft tumor growth with decreased tumor weight and prolonged tumor growth delay time. Our study discovered targeting MAPK signaling pathway could significantly improve tumor radioresponse of PDAC.

Supplementary Figure 6 from Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776

Supplementary Figure 4 from Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776

Supplementary Figure 7 from Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776

Supplementary Figure 5 from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair

Supplementary Table 3 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Figure 2 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Table 2 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Figure 1 from Small-Molecule Inhibitor BMS-777607 Induces Breast Cancer Cell Polyploidy with Increased Resistance to Cytotoxic Chemotherapy Agents

Supplementary Figure 5 from PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer

Supplementary Figures 1 Through 5 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Figure Legends from Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

Supplementary Figure Legends 1-10, Methods from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment

Supplementary Figure 4 from the Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Supplementary Figure 3 from the Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Supplementary Figure 9 from Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment

Supplementary Figure Legends 1-4 from The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Supplementary Figure 1 from The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Supplementary Figure 2 from the Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Supplementary Figure S2 from Safety and Clinical Response to Combined Immunotherapy with Autologous Inkt Cells and PD-1+CD8+ T Cells in Patients Failing First-Line Chemotherapy in Stage IV Pancreatic Cancer

Patient Derived Xenografts Demonstrate the Radiosensitizing Effect of Inhibiting MAPK Signaling Pathway in Pancreatic Ductal Adenocarcinoma